When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Obesity medicine could alter the field of orthopedics in 2025, as GLP-1s like Ozempic and Wegovy can help patients lose weight, making them candidates for procedures they previously could not receive, ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...